Analyst Reco. Alnylam Pharmaceuticals, Inc.

Stocks

ALNY

US02043Q1076

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 16/06/2026 BST			5-day change	1st Jan Change
281.90 ^USD	-2.05%		-5.30%	-29.11%

06-10	Alnylam, Genesis Pharma Expand Commercial Partnership Into 4 Nordic Markets	MT
06-09	Alnylam Pharmaceuticals, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 11:20 AM

Analyst Reco.

05-01	RBC Trims Price Target on Alnylam Pharmaceuticals to $445 From $450, Keeps Outperform Rating	MT
02-13	RBC Lowers Price Target on Alnylam Pharmaceuticals to $450 From $465, Keeps Outperform Rating	MT
01-20	RBC Cuts Price Target on Alnylam Pharmaceuticals to $465 From $500, Keeps Outperform Rating	MT
27/10/25	Intellia pauses gene therapy trials after patient suffers liver injury, shares slide	RE
06/10/25	Morgan Stanley Raises Price Target on Alnylam Pharmaceuticals to $475 From $405, Keeps Equalweight Rating	MT
19/09/25	RBC Raises Price Target on Alnylam Pharmaceuticals to $500 From $435, Keeps Outperform Rating	MT
04/08/25	Alnylam's Amvuttra Sales Exceeding Expectations by Sizable Margin, Oppenheimer Says	MT
04/08/25	Wolfe Upgrades Alnylam Pharmaceuticals to Peer Perform From Underperform	MT
04/08/25	Oppenheimer Upgrades Alnylam Pharmaceuticals to Outperform From Market Perform, Price Target is $490	MT
01/08/25	UBS Adjusts Price Target on Alnylam Pharmaceuticals to $550 From $403, Maintains Buy Rating	MT
21/07/25	Truist Securities Initiates Coverage on Alnylam Pharmaceuticals With Buy Rating, $385 Price Target	MT
07/07/25	RBC Raises Price Target on Alnylam Pharmaceuticals to $350 From $330, Keeps Outperform Rating	MT
02/05/25	UBS Adjusts Alnylam Pharmaceuticals Price Target to $349 From $331, Maintains Buy Rating	MT
17/04/25	BofA Adjusts Price Target on Alnylam Pharmaceuticals to $328 From $325, Keeps Buy Rating	MT
24/03/25	JPMorgan Upgrades Alnylam Pharmaceuticals to Overweight From Neutral, Adjusts Price Target to $328 From $280	MT
21/03/25	BofA Securities Raises Price Target on Alnylam Pharmaceuticals to $325 From $302, Keeps Buy Rating	MT
21/03/25	RBC Adjusts Price Target on Alnylam Pharmaceuticals to $330 From $310, Maintains Outperform Rating	MT
14/02/25	RBC Raises Price Target on Alnylam Pharmaceuticals to $310 From $300, Keeps Outperform Rating	MT
02/12/24	Mirae Asset Downgrades Alnylam Pharmaceuticals to Hold, Price Target is $236	MT
12/11/24	Alnylam Pharmaceuticals Shares Fall After Wolfe Downgrade	MT
12/11/24	Wolfe Downgrades Alnylam Pharmaceuticals to Underperform From Peer Perform, Price Target at $205	MT
16/10/24	Scotiabank Initiates Alnylam Pharmaceuticals at Sector Outperform With $305 Price Target	MT
20/09/24	China Merchants Initiates Alnylam Pharmaceuticals at Buy With $360 Price Target	MT
19/09/24	Alnylam Pharma Confident in ATTR-CM Treatment's Market Potential, Cautious on Regulatory Risks, RBC Says	MT
19/08/24	UBS Raises Alnylam Pharmaceuticals' Price Target to $308 From $288, Buy Rating Maintained	MT